Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
5.37M
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
195K
-
Shares change
-
+17.4K
-
Total reported value, excl. options
-
$2.3M
-
Value change
-
+$535K
-
Number of buys
-
11
-
Number of sells
-
-4
-
Price
-
$11.79
Significant Holders of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) as of Q3 2025
18 filings reported holding NEUP - Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share as of Q3 2025.
Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 195K shares
of 5.37M outstanding shares and own 3.64% of the company stock.
Largest 10 shareholders include AdvisorShares Investments LLC (58.6K shares), Prosperity Wealth Management, Inc. (29.8K shares), DIADEMA PARTNERS LP (21.5K shares), VANGUARD GROUP INC (21K shares), MILLENNIUM MANAGEMENT LLC (18.3K shares), JANE STREET GROUP, LLC (15.7K shares), GEODE CAPITAL MANAGEMENT, LLC (13K shares), Merck & Co., Inc. (10K shares), Persistent Asset Partners Ltd (4.91K shares), and UBS Group AG (2.17K shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.